FDA Issues Approvable Letter For SeaStar Medical's Selective Cytopheretic Device For Pediatric Patients
Portfolio Pulse from Benzinga Newsdesk
The FDA has issued an approvable letter for SeaStar Medical's Selective Cytopheretic Device for pediatric patients. This device is designed to treat patients in the ICU.
October 30, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical, a private company, has received FDA approval for its Selective Cytopheretic Device for pediatric patients. This could potentially increase the company's market share in the medical devices sector.
FDA approval is a significant milestone for any company in the medical devices sector. This approval could potentially increase SeaStar Medical's market share and competitiveness. However, as SeaStar is a private company, there is no direct impact on any US-listed stocks or ETFs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100